 Becton Dickinson and Cos NYSE: BDX pure-play diabetes spin-off Embecta Corp NASDAQ: EMBC has reported Q2 sales of 274.5 million, down 3.4 on a reported basis, down 1.3 on a constant currency basis. Of the decrease, 6.0 million was attributable to unfavorable. 